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DOI 10.1016/j.ccr.2010.06.003SUMMARYAs2O3 cures acute promyelocytic leukemia (APL) by initiating PML/RARA oncoprotein degradation, through
sumoylation of its PML moiety. However, how As2O3 initiates PML sumoylation has remained largely unex-
plained. As2O3 binds vicinal cysteines and increases reactive oxygen species (ROS) production. We demon-
strate that upon As2O3 exposure, PML undergoes ROS-initiated intermolecular disulfide formation and binds
arsenic directly. Disulfide-linked PML or PML/RARA multimers form nuclear matrix-associated nuclear
bodies (NBs), become sumoylated and are degraded. Hematopoietic progenitors transformed by an
As2O3-binding PML/RARA mutant exhibit defective As2O3 response. Conversely, nonarsenical oxidants elicit
PML/RARA multimerization, NB-association, degradation, and leukemia response in vivo, but do not affect
PLZF/RARA-driven APLs. Thus, PML oxidation regulates NB-biogenesis, while oxidation-enforced PML/
RARA multimerization and direct arsenic-binding cooperate to enforce APL’s exquisite As2O3 sensitivity.INTRODUCTION
The PML/RARA oncoprotein induces acute promyelocytic
leukemia (APL) through homo- and heterodimerization with
RXRA, leading to deregulation of transcription, differentiation
arrest, and enhanced self-renewal of leukemia-initiating blast
cells (LIC)(Kwok et al., 2006; Martens et al., 2010; Mikesch
et al., 2010; Zeisig et al., 2007; Zhu et al., 2007). As2O3 cures
APL through degradation of PML/RARA and the eradication of
LIC (Ghavamzadeh et al., 2006; Kogan, 2009; Mathews et al.,
2006; Nasr et al., 2008; Zhu et al., 2002). Arsenic atoms bind
vicinal cysteines of many target proteins, which results, among
others, in the poisoning of phosphatases or mitochondrial
enzymes from the respiratory chain (Miller et al., 2002). Thus,Significance
Arsenic trioxide cures many patients with PML/RARA-drive
PML/RARA degradation within distinct cellular domains, the
modified by two peptides, SUMO and ubiquitin, which lead to
PML sumoylation was not understood. We demonstrate that ar
tion of reactive oxygen species and direct binding. Disulfide-bo
degraded. Other oxidants trigger regression of PML/RARA-dr
utes to its therapeutical effect.
88 Cancer Cell 18, 88–98, July 13, 2010 ª2010 Elsevier Inc.like other metalloids, As2O3 elicits the formation of reactive
oxygen species (ROS) (Kawata et al., 2007).
As2O3 elicits PML/RARA degradation by targeting its PML
moiety. PML is an RBCC/TRIM protein that partitions between
a large nucleoplasmic fraction and nuclear matrix-associated
nuclear bodies (NBs) (Lallemand-Breitenbach and de The´,
2010). The nuclear matrix is biochemically-defined by resistance
to high salt/nuclease extractions. It was proposed to be associ-
ated with many processes (including DNA replication, transcrip-
tion and epigenetic silencing). Yet, its exact nature and the
existence of an actual morphologically definable structure has
been a matter of dispute (Stuurman et al., 1992a; Zaidi et al.,
2007). As2O3 elicits the transfer of the diffuse nucleoplasmic
PML fraction toward the nuclear matrix and NBs, independentlyn leukemia by targeting its PML moiety. Arsenic induces
nuclear bodies (NBs). PML or PML/RARA are sequentially
their degradation by the proteasome. How arsenic initiates
senic induces PML/RARA crosslinking through both produc-
und PML/RARA multimers then aggregate onto NBs and are
iven murine leukemias. Thus, PML/RARA oxidation contrib-
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Oxidation-Induced PML/RARA Crosslinking in APLof PML sumoylation, as demonstrated using a sumoylation-
defective PML mutant, PML3KR (Lallemand-Breitenbach et al.,
2001; Zhu et al., 1997). As2O3 also promotes sumoylation of
the critical PML K160 residue (Lallemand-Breitenbach et al.,
2001), which fosters recruitment of NB partners, including
Daxx transcriptional repressor or the SUMO-dependent ubiqui-
tin-ligase RNF4. In As2O3-exposed cells, RNF4 polyubiquitinates
PML, ultimately triggering its degradation on NBs (Lallemand-
Breitenbach et al., 2008; Tatham et al., 2008). Although key to
its antileukemia activity, how As2O3 actually fosters PML
matrix-association and sumoylation remains unknown.
RESULTS
Matrix-Associated PML Is Oxidized
The matrix-associated PML fraction is hypersumoylated (Lalle-
mand-Breitenbach et al., 2001). Conversely, deletion of the
coiled-coil of PML abrogates its association to the nuclear
matrix, NB formation, and sumoylation (see Figure S1A available
online). Thus, whereas As2O3 induces PML targeting to the
matrix and NB formation independently of sumoylation, matrix
association contributes to basal or As2O3-enhanced PML su-
moylation. We therefore questioned how As2O3 could promote
transfer from soluble diffuse nuclear PML to insoluble, matrix-
associated NBs. As2O3 controls protein phosphorylation and
ROS production. We could not confirm in our experimental
system (not shown) that As2O3-induced PML phosphorylation
by ERK1/2 controls PML sumoylation (Hayakawa and Privalsky,
2004). We then examined whether As2O3-induced ROS could
promote NB formation through PML disulfide formation, as inter-
molecular disulfide bonds were implicated in stabilizing the
nuclear matrix (Kaufmann et al., 1991; Stuurman et al., 1992b).
We observed that treatment with DTT (a dithiol reductant) of
nuclear matrix prepared in situ disrupted endogenous PML
NBs, without affecting lamin-B staining (Figure 1A). Similarly,
a 1 hr treatment of CHO cells stably expressing the PML-III iso-
form (CHO-PML) with the thiol alkylator N-ethylmaleimide (NEM)
disrupted basal PML NBs (Figure 1B). Finally, most CHO-PML
cells cultured for 10 days in the presence of the ROS scavenger
N-acetyl cysteine (NAC) lost basal NB formation (Figure 1C). NBs
were restored by a 3 day wash-out (not shown). Thus, cysteine
residues and ROS regulate NB biogenesis.
NBs are matrix-associated domains. When analyzed in the
absence of reducing agents (DTT or bME), the nuclear matrix
fraction of transiently PML-transfected CHO cells entirely con-
sisted of high molecular weight PML species (Figure 1D). DTT
disrupts disulfide bridges and may also reduce SOH or SOS
linkages. The observation that these high molecular weight
PML complexes reversed to monomeric species upon reduc-
tion, strongly suggested that matrix-associated PML consists
of intermolecularly disulfide-bound PMLmultimers. Accordingly,
pretreatment of CHO cells with NACprior to PML transfection led
to a dramatic decrease in the abundance of the high molecular
weight PML forms (Figure 1E). To formally demonstrate the exis-
tence of covalent PML multimers, we transiently expressed
(His)x6-PML-V with or without CFP-PML-III (PML isoforms of
different sizes; Figure 1F) in the presence of As2O3. Denatured
whole-cell lysates were analyzed under nonreducing conditions
with isoform-specific antibodies (Condemine et al., 2006). Incotransfected cells only, several, rather than one, high molecular
weight complexes were detected with the PML-V-specific anti-
body (Figure 1F). Only the highest species reacted with anti-
PML-III, implying that these were PML-III/PML-V multimers.
PML-multimerization was also demonstrated by immunoprecipi-
tating SDS-denatured lysates with anti-PML-III-specific sera,
followed by guanidinium denaturation and His-purification of
the (His)x6-PML-V-containing complexes. Under nonreducing
conditions, only cells expressing both PML isoforms yielded
high molecular weight PML-III- and PML-V-reactive conjugates,
which shifted to the monomeric state after reduction (Fig-
ure S1B). Finally, mass spectrometric analysis of high molecular
weight PML complexes purified under denaturing conditions
from As2O3-treated cells consisted primarily of PML peptides
(54%). Other detected proteins are most likely contaminants,
given that the most abundant one represented <6% of the total
peptides (Table S1). Collectively, these analyses strongly argue
against heterodimer formation with a distinct protein. Thus,
although we cannot rule out the existence of intramolecular
disulfide linkages, these data indicate that intermolecular PML
crosslinking by ROS-induced disulfides is associated with its
presence in the nuclear matrix and with NB-formation.
We next investigated whether oxidants enhance disulfide-
bound PML multimerization. A short exposure to therapeutic
levels of As2O3 (Figure 1G) or to other oxidants, such as H2O2
or CdCl2 (not shown), massively increased the amounts of cova-
lent PMLmultimers in CHO cells transiently overexpressing PML
(Figure 1G, not shown). In stable CHO transfectants, oxidants
similarly induced PML multimerization, whereas arsenical also
promoted PML sumoylation (Figure 1H). Formation of covalent
multimers in transiently PML-transfected CHO cells was abro-
gated by pretreatment with NEM or NAC (Figures 1I and 1J). If
PML covalent multimerization by ROS is indeed the primary
event initiating As2O3 effects, other oxidants should mimic
As2O3-enhanced NB biogenesis. Yet, strong oxidants (CdCl2,
H2O2.) disrupt NBs in cultured cells (reviewed in Lallemand-
Breitenbach and de The´, 2010), possibly because these
agents fully oxidize some critical cysteines into cysteic acid,
precluding disulfide formation and thus dissociating NBs (data
not shown). We thus examined whether paraquat, an acute
ROS inducer (Black et al., 2008), would regulate NB formation
in vivo, a setting where ROS levels are likely more controlled.
Although CHO-PML cells grown ex vivo displayed prominent
NBs, those were barely detectable when these cells were grown
as xenografts in nude mice (Figure 1K). This could suggest that
the microenvironment (notably oxygen tension) in vivo does not
favor NB formation, whereas ex vivo culture under hyperoxic
conditions evokes NB aggregation. Critically, paraquat or As2O3
treatment of mice bearing CHO-PML xenografts elicited a
dramatic increase in NB formation (containing both PML and its
partner daxx) (Figure 1K). Western blot analysis under non-
reducing conditions showed the occurrence of PML multimers
in CHO-PML xenografts derived from oxidant-treated mice
(Figure 1L). Enhanced NB formation by endogenous murine
PML was also observed in bone marrow cells on treatment with
paraquat (Figure 1K) or As2O3 treatment (not shown). Altogether,
these data demonstrate that, in vivo, ROS inducers mimic As2O3
as to the regulation of PML oxidation, NB formation, and partner
recruitment.Cancer Cell 18, 88–98, July 13, 2010 ª2010 Elsevier Inc. 89
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Figure 1. As2O3-Induced Disulfide Formation Targets PML to the Nuclear Matrix
(A) PML (red) and LaminB (green) staining of MRC5 cells. In situ nuclear matrix preparation were treated or not treated with DTT (10 mM, 10 min) prior to antibody
labeling. The scale bar represents 5 mm.
(B) Prefixation treatment (pre-T) with NEM of CHO-PML cells prior to nuclear matrix preparation disrupts NBs. The scale bar represents 5 mm.
(C) Ten days of N-acetyl-cysteine (NAC) treatment decreases the number of PML bodies in CHO-PML cells. The scale bar represents 5 mm.
(D) Total cell lysates (T) or nuclear matrix (NM) fractions of CHO cells transiently transfected with PML were analyzed in nonreducing (b-ME, top) or reducing
(+b-ME, bottom) conditions.
(E) Pretreatment with NAC dramatically reduces formation of PML multimers in transiently transfected CHO cells.
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Figure 2. PML/RARA Oxidation Promotes NB Formation
(A) Shown on the left are oxidant-treated murine APL cells (from hPML/RARA transgenic mice), under reducing or nonreducing conditions. As shown on the right,
As2O3 (10 mM, 1 hr) induces PML/RARA multimerization and attachment to the matrix. Cells were fractionated into total (T) and nuclear matrix (NM) extracts.
(B) The top row shows anti-hPML antibody staining of hPML/RARA-transformed mouse bone marrow progenitors treated or not treated with As2O3 for 1 hr.
/
and +/+ refer to the pml background of the transformed cells. The scale bar represents 5 mm. The bottom row shows localization of SUMO-1, SUMO-2, or daxx,
after 1 hr exposure to As2O3 of PML/RARA-transformed pml
/ progenitors.
(C) As2O3-induced PML/RARA degradation in pml
/ or pml+/+ transformed MEF cells.
(D) Schematic model of As2O3-induced PML/RARA trafficking.
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Oxidation-Induced PML/RARA Crosslinking in APLPML/RARA Oxidation Triggers Its Matrix-Targeting,
NB Reformation, and APL Remission
Ex vivo, As2O3 and its FLAsH analog induced PML/RARA
hypersumoylation (Figure 2A). These arsenicals, as well as
H2O2, elicited intermolecular disulfide-bound PML/RARA multi-
mer formation, in both transduced MEF cells and murine APL
blast cells (Figure 2A). PML/RARA multimers became matrix-
associated upon As2O3 treatment. As2O3 also induced the
coalescence of PML/RARA microspeckles (together with(F) CHO cells were transiently transfected with (His)X6-PML-V and/or CFP-PML
labeled with the indicated antibodies. The arrows indicate the different PML
PML-III/PML-V multimer.
(G) As2O3 treatment increases PML multimerization in transiently transfected CH
(H) Stably expressed PML exhibits oxidant stress-mediated multimerization. PA
Treatment for 1 hr. PML monomers, multimers, and SUMO/ubiquitin conjugates
2008), are indicated.
(I) Pretreatment of PML-transfected CHO cells with NEM for 1 hr inhibits As2O3-
protein. Analysis was performed in nonreducing conditions.
(J) Pretreatment of PML-transfected CHO cells with NAC for 3 days inhibits As2O
(K) NB formation in vivo after paraquat or As2O3 treatment of nude mice xenograft
PML (red) and anti-daxx (green) antibodies. The scale bar represents 10 mm. A zo
show bone marrow cells with endogenous pml. The scale bar represents 5 mm.
(L) Western blot analysis of CHO-PML xenografts after in vivo As2O3 or paraquatSUMO-1/2/3 and daxx) into typical NBs in either pml+/+ or
pml/ transduced hemopoietic progenitors or fibroblasts
(Figure 2B).Whereas the kinetics of NB reformationwere delayed
in pml/ cells, PML/RARA was ultimately fully degraded upon
As2O3 treatment in both settings (Figure 2C). These data demon-
strate that As2O3-induced PML/RARA multimerization results
in its targeting to thematrix, drives NB reformation and ultimately
allows its sumoylation/degradation, in the same manner as
for PML (Figure 2D).-III. Total extracts in nonreducing (top) or reducing (bottom) conditions were
complexes, multimers are denoted (PML)2. The arrowheads indicate mixed
O cells.
O and FlAsH are 106 M, As203 and CdCl2 are 105 M, and H202 is 103 M.
(unambiguously identified in previous studies (Lallemand-Breitenbach et al.,
or H2O2-induced PML multimer formation. The asterisk denotes a nonspecific
3- induced PML dimerization.
ed with CHO-PML cells. Top left panels show tumor sections stained with anti-
om (23) on representative cells is shown in the top right panels. Bottom panels
exposure. Arrowheads indicate covalent PML multimers. See also Figure S1.
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Figure 3. PML/RARA Oxidation Promotes APL Response In Vivo
(A) Treatment of mice with paraquat or As2O3 for 2 days induce oxidative stress and g-H2AX phosphorylation in APL bone marrow cells.
(B) Treatment of APL mice with oxidants (As2O3 or paraquat) induces PML/RARA multimerization, sumoylation (1 hr, left panel) and degradation (3 days,
right panel) in APL bone marrow cells. Presence of b-ME is indicated. A long exposure of the gel, allowing detection of the (PML)2 species after a 1 hr exposure
to oxidants, is shown below.
(C) NB reformation in bone marrow cells of APL mice treated for 3 hr with As2O3 or Paraquat. Immuno-fluorescence with anti-daxx or hPML antibodies to detect
hPML/RARA. The scale bar represents 5 mm.
(D) Tumor regression induced by paraquat or As2O3 is specific for PML/RARA-driven APL. Spleen weight of the two types of APL mice at 3 days. Mean ± SD of
three independent experiments is shown. **p < 0.01; ***p < 0.001.
(E) FACS analysis of bone marrow cells of APL mice treated or not treated for 3 days with As2O3 or paraquat. Both PML/RARA- and PLZF/RARA-driven murine
APLs are shown. The antibodies used and the cell distributions are indicated.
(F) May Gru¨nwald Giemsa staining of bone marrow cells of PML/RARA APL mice treated with As2O3 or paraquat for 3 days.
(G) Same as in (E) with treatment with suboptimal doses of RA that fails to significantly differentiate (Nasr et al., 2008).
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Oxidation-Induced PML/RARA Crosslinking in APLWe then treated APL mice with paraquat or As2O3. Both
agents induced oxidative stress in bone marrow APL cells,
as measured by phospho-gH2AX (Figure 3A). Oxidation by para-
quat was generally more pronounced than that induced by
As2O3, as measured by homocysteine formation and DCF-HDA
labeling (not shown). After 1 to 3 hr in vivo treatment, both agents
induced PML/RARA multimerization and sumoylation, which
were accompanied by NB reformation (Figures 3B and 3C). At
day 3, both treatments led to PML/RARA loss in the APL blasts
(Figure 3B).92 Cancer Cell 18, 88–98, July 13, 2010 ª2010 Elsevier Inc.Critically, both paraquat and As2O3 triggered a dramatic APL
regression, as assessed by spleen weight (Figure 3D), although
the bone marrow remained essentially leukemic at day 3.
Consistent with the greater oxidative stress, paraquat was
generally more active than As2O3 in eliciting NB reformation
and APL regression. In animals treated with either agent, PML/
RARA degradation was accompanied by loss of Kit expression
(a marker commonly expressed by early clonogenic progenitors)
and an increase in CD11b expression (Figure 3E). Yet, at this time
point, As2O3 or paraquat treatments were not accompanied by
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Figure 4. As2O3 Binds Directly to PML
(A) Fluorescent diarsenical labels PML bodies in in situ-prepared nuclear matrix of CHO-PML cells. The scale bar represents 5 mm.
(B) Streptavidin pull-down shows that As-biotin binds to PML in CHO-PML-treated cells.
(C) Direct binding of As2O3 on bacterially produced full-lengthMBP-PML. MBP-Sp100 is a negative control. Arsenic content wasmeasured by atomic absorption.
(D) Shown on the left are stable CHO-PML cells after treatment with As2O3 or PAO for 1 hr. Shown on the right is a comparison of As2O3 (10
5M), FlAsH (106M),
and PAO (105M) in the same cells.
(E) FRAP analysis of CFP-PML and YFP-SUMO-1 exchange rates on NBs of transduced MEF pml/ cells treated or not with 106 M As2O3. See also Figure S2.
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ously shown for As2O3 (Lallemand-Breitenbach et al., 1999).
As2O3 does not affect APL driven by the variant PLZF/RARA
fusion (Rego et al., 2000). Critically, paraquat did not impede
growth, nor did it induce Kit loss or CD11b induction of these
variant APLs (Figures 3D and 3E). Thus, in vivo, paraquat specif-
ically targets PML/RARA, rather than inducing nonspecific
toxicity. In classical PML/RARA-driven APLs, suboptimal doses
of retinoic acid (RA, 1.5 mg) induce transient differentiation, but
do not affect LIC self-renewal, because of incomplete PML/
RARA degradation (Nasr et al., 2008). Consequently, upon
3 days of this RA treatment, marrow cells retained an immature
phenotype. When combined with RA 1.5, paraquat enhanced
granulocytic differentiation (Figure 3G) and APL regression (not
shown), as previously shown for As2O3 (Nasr et al., 2008). Taken
together, our finding that paraquat mimics the biological effects
of As2O3 on PML and PML/RARA (oxidation, NB formation,
partner recruitment, degradation, and APL regression) implies
that ROS production contributes to As2O3 therapeutic activity
in PML/RARA-driven APL.
Arsenic Binds to PML
PML is a cysteine-rich protein with a dicysteine motif (C212/
C213), which could directly bind As2O3. Synthetic FlAsH diarsen-ical cooperatively binds two CC motifs (Luedtke et al., 2007),
upon which it becomes fluorescent (Griffin et al., 2000). Using
FlAsH, labeling of PML NBs was distinctly observed in CHO-
PML cells and even more prominently in in situ nuclear matrix
preparations (Figure 4A). To determine whether PML directly
binds to arsenic, we exposed CHO-PML cells to an arsenic-
biotin (As-biotin) derivative. As-biotin conjugated proteins were
purified on a streptavidin column and eluates analyzed by
western blotting with anti-PML antibodies. Only cells exposed
to As-biotin yielded detectable PML proteins (Figure 4B). Finally,
we quantified by atomic absorption arsenic binding on purified
MBP-PML produced in bacteria. We detected arsenic atoms
(on average 0.5 arsenic atoms per polypeptide) when 10 mM
As2O3 was added directly onto the purified MBP-PML proteins
or even in culture media (Figure 4C). Arsenic binding was fully
reversed by dithiols, but much less by monothiols. Another
NB-associated protein, Sp100, did not bind arsenic atoms.
FlAsH diarsenical initiated PML sumoylation and degradation
more efficiently than As2O3, which may bind a single or two CC
pairs (Figure 4D). That FlAsH became fluorescent (Figure 4A)
suggests that it actually binds two CC pairs. Conversely, the
bulky monoarsenical oxidant phenylarsine oxide (PAO), which
only binds a single CC pair, promoted some PML disulfide
formation (presumably through generation of ROS), yet itCancer Cell 18, 88–98, July 13, 2010 ª2010 Elsevier Inc. 93
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Oxidation-Induced PML/RARA Crosslinking in APLparadoxically antagonized both basal PML matrix attachment
and sumoylation (Figure 4D; Figure S2). Moreover, PAO
completely abolished As2O3 effects on PML sumoylation at equi-
molar concentrations. These unexpected findings could support
the idea that two arsenic atoms, but not one, may crosslink two
PML polypeptides, mimicking disulfides (Luedtke et al., 2007)
and promoting sumoylation.
We then assessed PML exchange rates on NBs by FRAP. In
the absence of As2O3, PML was dynamically associated with
NBs, in keeping with previous studies (Figure 4E) (Boisvert
et al., 2001; Weidtkamp-Peters et al., 2008). Exposure to
As2O3 elicited complete immobilization of CFP-PML, but not
of YFP-SUMO-1 (which may be conjugated to many other
NB-associated proteins). Such dramatic immobilization most94 Cancer Cell 18, 88–98, July 13, 2010 ª2010 Elsevier Inc.likely directly reflects PML crosslinking by disulfide formation
and/or arsenic binding.
C212 Contributes to Response to As2O3
The C212/C213 motif may be directly implicated in arsenic
binding. The outer PML-labeled shell formed by the PMLC212A,
C213A, or C212/213A mutants lost the FlAsH labeling observed
in normal NBs. Unexpectedly, the PML-negative inner core
accumulated FlAsH in the mutant (Figure 5A), an observation
that deserves further exploration. PMLC212A similarly exhibited
sharply diminished As-biotin binding (Figure 5B). Thus the PML
C212/213 dicysteine motif contributes to direct arsenic binding.
Contrasting with wild-type PML, stable expression of
PMLC212A or PMLC213A mutants in CHO cells resulted in
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Oxidation-Induced PML/RARA Crosslinking in APLstrong diffuse nuclear PML labeling with only one or two
abnormally large NBs. Importantly, those failed to accumulate
daxx and SUMO (Figures 5C and 5D), although they still re-
cruited GFP-UBC9, probably through PML RING (Figure S3).
The PMLC212A and PMLC213A mutants both exhibited an
altered basal or As2O3-induced sumoylation (Figure 5E) and
failed to be degraded (Figure 5F). These two PML mutants
thus mimic inactivation of the key K160 sumoylation site.
Whereas the diffuse nuclear fraction of the wild-type PML
protein was entirely targeted onto NBs upon As2O3 exposure
(Lallemand-Breitenbach et al., 2001; Zhu et al., 1997), that of
PMLC212A was essentially As2O3 insensitive (Figure 5C). This
mutant was also defective for As2O3-enhanced association
with the nuclear matrix (Figure 5G). It nevertheless showed
some basal matrix-association and As2O3-enhanced disul-
fide-mediated crosslinking. Altogether, these data indicate
that C212 contributes not only to direct As2O3 binding, but
also to basal NB biogenesis and PML sumoylation. Mutations
of neighboring C148, C151, or C227 cysteines did not affect
matrix association, NB biogenesis, FlAsH binding, or As2O3-
induced degradation (not shown). Collectively, our findings
converge on a model for NB assembly, integrating both the
initial role of ROS-mediated PML dimerization and direct
arsenic-binding, to ultimately control PML sumoylation (Fig-
ure 5H, see Discussion).Mutant PML/RARAC212/213A or C212A retained the ability to
transform primary hemopoietic progenitors in a methyl-cellulose
replating assay, at least up to the third passage, like the wild-
type PML/RARA oncoprotein. These mutants formed nuclear
microspeckles (Figure 6A), which, as expected, were not labeled
by FlAsH (not shown). For both mutants, basal PML/RARA
sumoylation was altered (Figure 6B). Similarly, NB reformation,
enhanced sumoylation, daxx recruitment, and PML/RARA
degradation upon As2O3 exposure were all lost for both mutants
(Figures 6A and 6B), again mimicking PML/RARAK160R (Zhu
et al., 2005). Moreover, multimer formation was significantly
decreased upon As2O3 exposure (Figure 6C). Finally, PML/
RARAC212/213A- or PML/RARAC212A-transformed progeni-
tors were completely resistant to As2O3-induced loss of Kit
expression (Figure 6D), a surrogate for the response to arsenic
in vivo (Lallemand-Breitenbach et al., 2008). Thus, C212 is
required to elicit As2O3-induced PML/RARA degradation and,
ultimately, APL response to As2O3.
DISCUSSION
By implicating ROS-mediated PML oxidation and direct As2O3
binding in therapy response, our results provide mechanistic
insights into the basis of APL cure by As2O3 and have broad
implications for the physiological control of NB formation.Cancer Cell 18, 88–98, July 13, 2010 ª2010 Elsevier Inc. 95
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Oxidation-Induced PML/RARA Crosslinking in APLWe first demonstrate that ROS regulate NB-biogenesis in vivo,
explaining the abundance of NBs in multiple stress conditions or
in cells exposed to high oxygen concentrations, such as endo-
thelial cells (Koken et al., 1995; Lallemand-Breitenbach and de
The´, 2010). NBs are nuclear matrix domains and disulfides
were previously implicated in nuclear matrix formation (Kauf-
mann et al., 1991; Stuurman et al., 1992b). PML is the first
example of a protein organizing a nuclear domain in a ROS-
dependent manner, suggesting that PML may be a ROS sensor.
Both ROS and PML have been implicated in multiple biological
processes, notably DNA damage response, senescence, and
stem cell self-renewal, as well as in the fine-tuning of some
critical signaling pathways, including HIF1a or PTEN/AKT
(Song et al., 2008; Trotman et al., 2006; Bernardi and Pandolfi,
2007; Ito et al., 2008; Pearson et al., 2000). PML NB formation
could thus mediate some effects of basal ROS. In cellulose syn-
thase, cysteines arranged in a zinc finger become engaged into
multiple intermolecular disulfides upon ROS exposure (Kurek
et al., 2002). This ROS-induced, oxidation-mediated, transition
is responsible for the action of herbicides on cellulose synthase
activity. PML, which harbors three zinc fingers, forms several
disulfide bridges (data not shown), likely all required for full matrix
association and PML sumoylation. This could explain why,
despite formation of some disulfide bridges, the C212A mutant
exhibits a defective sumoylation. Matrix association and/or
sumoylation might also require an interchain zinc finger (Calla-
ghan et al., 2005), itself possibly involving C212. Future studies
should identify all cysteines involved in ROS-sensitive PML
dimerization, define their connectivity, and elucidate the struc-
tural details of multimer formation.
Arsenic elicits both PML association with the nuclear matrix
and its sumoylation (Lallemand-Breitenbach et al., 2001). These
are presumably two consecutive steps, becausemutants that do
not associate with the nuclear matrix are not sumoylated,
whereas nuclear matrix-associated PML is consistently entirely
polysumoylated (Figure 4D) (Lallemand-Breitenbach et al.,
2001). This suggests the following model to explain NB-biogen-
esis and PML sumoylation (Figure 5H): basal, As2O3- or para-
quat-induced ROS promote disulfide-mediated covalent
bridging of preassembled noncovalent PML or PML/RARA
dimers, allowing them to multimerize, acquire nuclear matrix
features, and thus form primary NBs. These multimers are
subsequently sumoylated. SUMO conjugation of PML in trans
by the PML RING-bound UBC9, rather than in cis (similarly to
receptor tyrosine kinase trans-phosphorylation), could explain
why matrix-associated PML mesh is so efficiently sumoylated.
This sequential model accounts for the observation that NAC
or NEM blunts NB formation (Figure 1) and As2O3 response in
APL cells (Miller et al., 2002). Yet, other mechanismsmay coexist
and cooperate with the latter to enforce As2O3-triggered PML
sumoylation. Indeed, As2O3 or FlAsH directly bind to PML and
may trigger sumoylation of PML or PML/RARA monomers
(Figures 1H and 4D, for example), either by enhancing UBC9
binding onto PML (Zhang et al., 2010) or by forming As2O3-medi-
ated intramolecular bridges (Luedtke et al., 2007). Biarsenicals
could also contribute to formation of intermolecular PML cross-
links. In that respect, the complete immobilization of PML NBs
upon As2O3 in FRAP experiments, strongly argues for a distinct,
tighter, type of PML association. Structural and physicochemical96 Cancer Cell 18, 88–98, July 13, 2010 ª2010 Elsevier Inc.studies should define the arrangement of arsenic atoms within
PML multimers and determine the functional consequences of
binding. The sumoylation pathway, which relies on some thiol
enzymes, is highly ROS sensitive (Bossis and Melchior, 2006;
Han et al., 2010). PML sumoylation allows NBs to sequester
many partner proteins (Lallemand-Breitenbach and de The´,
2010), suggesting that ROS could trigger partner sequestration.
Given the proposed role of PML as a SUMO E3 ligase (Quimby
et al., 2006) and the fact that most partners may themselves
undergo sumoylation, PML NB aggregation could contribute to
their stress-regulated sumoylation (Saitoh and Hinchey, 2000).
Our data suggest that As2O3-induced ROS and direct binding
both contribute to the curative effect of As2O3 in APL. ROS
primarily control NB formation (and indirectly sumoylation)
in vivo, whereas As2O3 dramatically enhances sumoylation
both ex vivo and in vivo. Critically, nonarsenical ROS-inducers
(paraquat, a-TOS; Freitas et al., 2009) induce PML/RARA
degradation, dramatic regressions, and even promote long-
term survival in murine APLs (Figure 3 and E. Rego, personal
communication). Iron deprivation-induced ROS similarly initiates
apoptosis and differentiation in APL cells (Callens et al., 2010).
This strongly suggests that As2O3-induced ROS significantly
contribute to therapy response in vivo. Conversely, there is
circumstantial evidence that direct As2O3 binding is also impor-
tant, as in vivo, we detected oxidant-induced sumoylation of
PML/RARA with oxidative stresses significantly greater than
those imposed by As2O3. Such higher clinical efficiency of
As2O3 could reflect its ability to bind to an exquisitely sensitive
site in the protein, which controls its sumoylation, and to cross-
link PML, allowing tight matrix association.
That As2O3-induced ROS significantly contribute to its clinical
efficacy, suggests that human APL may be susceptible to
a variety of other ROS-inducers. In that respect, the standard
APL chemotherapy, anthracyclines, induces massive ROS pro-
duction (Berthiaume andWallace, 2007).When used in combina-
tion with RA, anthracyclines dramatically enhances its long-term
efficacy, in the same manner as As2O3 (Lallemand-Breitenbach
et al., 1999; Nasr et al., 2008; Wang and Chen, 2008). Anthracy-
clines-induced ROS may thus contribute to their antileukemia
effects. Conversely, lack of ROSsensitivity of PLZF/RARA-driven
APLs, together with partial RA-resistance (Nasr et al., 2008), may
account for their resistance to RA/anthracycline therapy (Licht
et al., 1995). Collectively, our studies identify ROS as critical
regulators not only of PML NB biogenesis, but also of PML/
RARA degradation, making an essential contribution to APL
cure by As2O3. Future studies should establish the respective
contribution of ROS induction anddirect binding in APL response
to As2O3, by identifying mutations uncoupling these two pheno-
types and testing their in vivo importance for As2O3 response.EXPERIMENTAL PROCEDURES
Antibodies
Homemade rabbit and chicken anti-hPML antibodies were used as described
(Lallemand-Breitenbach et al., 2008). PML isoform-specific antibodies have
been previously characterized (Condemine et al., 2006). Anti-mouse pml
monoclonal was from Upstate Biochemicals. Rabbit polyclonal anti-
RARA115 was a kind gift of Pierre Chambon. The rabbit polyclonal anti-
RXRA (D20) and anti-daxx (M-112), and goat polyclonal anti-LaminB (M-20)
antibodies were from Santa Cruz Biotechnology. Anti–SUMO-1 (GMP-1) and
Cancer Cell
Oxidation-Induced PML/RARA Crosslinking in APLrabbit polyclonal anti-SUMO-2/3 antibodies were from Zymed Laboratories.
Anti-phospho-gH2AX (rabbit 20E3) was from Cell Signaling. All primary anti-
bodies were revealed by AlexaFluor 488 or 594-labeled secondary antibodies
from Molecular Probes.
Cell Lines and Treatments
CHO, MRC5, COS, and pml/ or pml+/+ MEF cells were grown in 10% fetal
calf serum (FCS)-supplemented DMEM medium (GIBCO). Primary mouse
APL blast cells were obtained from the bone marrow of serially transplanted
mice (Nasr et al., 2008) and cultured in RPMI medium supplemented with
10% FCS, IL-3, IL-6, and SCF (GIBCO). CHO-PML cells stably express PMLIII
or the indicated mutants.
As2O3 (Fluka) treatment was performed as indicated at 1 mM or 10 mM for
1 hr, or at 1 mM for 16 hr to induce PML degradation. PML/RARA degradation
was induced by a 16 hr 0.1 mM As2O3 treatment of pml
/ MEF cells and an
8-day 6 3 108 M treatment of methylcellulose cultured transformed mouse
progenitors. CHO cells were treated with 1 mM TC-FlAsH (FlAsH, Molecular
Probes), 10 mM CdCl2 (Fluka), or 10 mM PAO (Sigma) for 1 hr, or with 1 mM
H2O2 (Sigma) for 30 min. Dithiarsolan-biotin conjugate (As-biotin) was kindly
given by Kenneth L. Kirk and used at 10 mM for 1 hr. Cells were pretreated
with 100 mM NEM (Sigma) for 1 hr before adding 10 mM As2O3 or 1 mM
H2O2. Buffered NAC was used at a concentration of 1 mM.
Western Blot Analysis, In Situ Nuclear Matrix Preparations
For all PML extractions, NEM (10 mM) was added to the lysis buffer to prevent
artifactual de novo formation of disulfides. For analysis under non-reducing
conditions, b-Mercaptoethanol was omitted from the standard Laemmli buffer.
Cell lysates were resolved on 7% or 3 to 10% gradient SDS-PAGE gels.
Nitrocellulose membranes were blocked in 5% milk, incubated with specific
antibodies and detected with the SuperSignal WestPico (Pierce) chemilumi-
nescent substrate.
In situ nuclear matrices were prepared as described (Stuurman et al., 1990)
and used for immunofluorescence or resuspended in Laemmli buffer for
western blot analysis.
Animal Experiments
Mouse experiments were repeated three times. Animals were handled
according to the guidelines of institutional animal care committees, using
protocols approved by the ‘‘Comite´ Re´gional d’Ethique Expe´rimentation
Animale (CREEA) n4.’’ Paraquat (Sigma, 25 mg/kg) was injected intraperito-
neally daily in PML/RARA APLmice treated or not with RA 1.5mg slow-release
pellets (Innovative Research of America) for 3 or 5 days. Arsenic was delivered
as previously described (Nasr et al., 2008). APL cells were obtained from the
bone marrow and spleen (Nasr et al., 2008). Flow cytometry determination
of differentiation-associated surface antigens (Mac1/Gr1/Kit) was performed
as reported (Nasr et al., 2008). PLZF/RARA+RARA/PLZF-driven APL were
obtained from P.P. Pandolfi and propagated exactly as previously described
(Nasr et al., 2008).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures and one table and can be found with this article online at
doi:10.1016/j.ccr.2010.06.003.
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